Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

2020 ◽  
Vol 19 (11) ◽  
pp. 2298-2307
Author(s):  
Nicolas Floc'h ◽  
Sangbin Lim ◽  
Sue Bickerton ◽  
Afshan Ahmed ◽  
Jonathan Orme ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Egfr Mutations ◽  
Next Generation ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase

scholarly journals BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

PLoS Medicine ◽  
2007 ◽  
Vol 4 (10) ◽  
pp. e315 ◽  
Author(s):  
Daniel B Costa ◽  
Balázs Halmos ◽  
Amit Kumar ◽  
Susan T Schumer ◽  
Mark S Huberman ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Egfr Mutations ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Lung Cancers ◽  
Egfr Tyrosine Kinase ◽  
Induced Apoptosis

scholarly journals Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

2018 ◽  
Vol 17 (5) ◽  
pp. 885-896 ◽  
Author(s):  
Nicolas Floc'h ◽  
Matthew J. Martin ◽  
Jonathan W. Riess ◽  
Jonathan P. Orme ◽  
Anna D. Staniszewska ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase ◽  
Exon 20
Sign in / Sign up

Export Citation Format

Share Document